MedTrace Logo

Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Paraquat Poisoning Induced Lung Injury

NCT02444858 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2015-05-15

No results posted yet for this study

Summary

Phase I-II Clinical Trial-Safety and efficacy of umbilical-cord-derived mesenchymal stem cell (UC-MSC) in patients with paraquat poisoning induced lung injury, randomized,single blind, controlled prospective study.

Conditions

  • Paraquat Poisoning
  • Lung Injury

Interventions

BIOLOGICAL

UCMSC group

Human umbilical cord MSCs are transplanted by intravenous injection(5×10\^5/kg) ，once a day,a total of three times.

OTHER

Control group(Normal saline)

Normal saline in same volume as MSCs are transplanted to patients.

Sponsors & Collaborators

  • Ivy Institute of Stem Cells Co. Ltd

    collaborator INDUSTRY

  • Affiliated Hospital to Academy of Military Medical Sciences

    lead OTHER

Principal Investigators

  • Bing Liu, M.D. · 307-IVY Translational Medicine Center

  • Zewu Qiu, M.D. · Department of poisoning treatment,Affiliated Hospital to Academy of Military Medical Sciences

  • Haochun Wang, M.D. · Department of poisoning treatment,Affiliated Hospital to Academy of Military Medical Sciences

  • Xiaobo Peng, M.D. · Department of poisoning treatment,Affiliated Hospital to Academy of Military Medical Sciences

  • Chunyan Wang, M.D. · Department of poisoning treatment,Affiliated Hospital to Academy of Military Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2017-05-31
Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02444858 on ClinicalTrials.gov